Full text
Earnings transcript
Read the complete earnings call transcript.
AZN
AstraZeneca PLC
$165.41
-1.27
(-0.76%)
| Exchange: | NYSE |
| Market Cap: | 256.53B |
| Shares Outstanding: | 716.59M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – GeneralView industry performance | |||||
| CEO: | Pascal Claude Roland Soriot | |||||
| Full Time Employees: | 96100 | |||||
| Address: |
| |||||
| Website: | https://www.astrazeneca.com |
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company’s extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Click to read more…
Revenue Segmentation
AZN full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of AstraZeneca, ticker AZN, one of the heavyweights in the global pharmaceutical space. If you’re looking to understand what makes this company tick, whether it’s a solid investment for your portfolio, or just curious about its future prospects, you’re in the right place. Let’s break it all down together, so stick around and let’s get started! Alright, before we get into the nitty-gritty, let’s set…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 45,811,000 | 54,073,000 | 58,739,000 |
| Gross Profit | 37,543,000 | 43,866,000 | 48,106,000 |
| EBITDA | 13,422,000 | 15,438,000 | 19,829,000 |
| Operating Income | 8,193,000 | 10,003,000 | 13,743,000 |
| Net Income | 5,955,000 | 7,035,000 | 10,255,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 101,119,000 | 104,035,000 | 114,074,000 |
| Total Liabilities | 61,953,000 | 63,164,000 | 65,355,000 |
| Total Stockholders Equity | 39,143,000 | 40,786,000 | 48,667,000 |
| Total Debt | 28,622,000 | 30,114,000 | 29,703,000 |
| Cash and Cash Equivalents | 5,840,000 | 5,488,000 | 5,711,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 10,345,000 | 11,861,000 | 15,191,507 |
| Capital Expenditure | -3,778,000 | -4,586,000 | -2,810,000 |
| Free Cash Flow | 6,567,000 | 7,275,000 | 11,765,000 |
| Net Income | 6,899,000 | 8,691,000 | 10,225,000 |
| Net Change in Cash | -346,000 | -208,000 | 237,825 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 78,299,054.612 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 83,194,210.166 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 81,134,066.667 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 41,810,263.794 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 44,642,209.728 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 43,450,370.550 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 24,122,637.675 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 26,104,721.956 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 25,270,551.476 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 30,429,072.282 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 32,331,458.497 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 31,530,832.541 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 16.180 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 16.710 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 15.440 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 11 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 4 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: AZN demonstrates strong revenue growth and consistent net income as per the latest income statements, supported by positive free cash flow trends from cash flow statements. This indicates operational efficiency and financial stability, critical for sustaining long-term growth.
- Innovative Product Portfolio: Insights from earnings call transcripts and news highlight AZN’s focus on innovation in key therapeutic areas, driving revenue as evidenced by product segment data. This positions the company favorably within the pharmaceutical industry.
- Strong Market Position: With a competitive market cap and a solid presence in the global healthcare sector (as per company profile data), AZN benefits from brand recognition and a large employee base, enhancing its operational capacity.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates AZN intrinsic value between $182.80 – $232.72 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AZN valuation
Is AstraZeneca PLC (AZN) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for AstraZeneca PLC (AZN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AZN a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AZN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AZN’s P/E ratio?
You can see AZN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AZN?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AZN a good long-term investment?
Whether AZN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AZN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.76
Trading Metrics:
| Open: | 166.97 | Previous Close: | 166.68 | |
| Day Low: | 164.99 | Day High: | 167.18 | |
| Year Low: | 153.41 | Year High: | 212.71 | |
| Price Avg 50: | 162.05 | Price Avg 200: | 181.05 | |
| Volume: | 3.356M | Average Volume: | 3.092M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
